Refractory epilepsy: mechanisms and solutions

References

• Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry 61, 433–443 (1996).
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. 71, 576–586 (1996).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry 75, 1376–1381 (2004).
   PubMed Web of Science ®Google Scholar
• Engel J Jr, Pedley TA. Introduction: what is epilepsy? In: Epilepsy: a comprehensive textbook (Volume 1). Engel J Jr, Pedley TA (Eds), Lippincott-Raven, PA, USA, 1–10 (1997).
   Google Scholar
• Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22, 489–501 (1981).
   PubMed Web of Science ®Google Scholar
• Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification of epilepsies and epileptic syndromes. Epilepsia 30, 389–399 (1989).
   PubMed Web of Science ®Google Scholar
• McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Ann. Rev. Physiol. 63, 815–846 (2001).
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Rev. Neurosci. 5, 553–564 (2004).
   PubMed Web of Science ®Google Scholar
• Mulley JC, Scheffer IE, Petrou S, Berkovic SF. Channelopathies as a genetic cause of epilepsy. Curr. Opin. Neurol. 16, 171–176 (2003).
   PubMed Web of Science ®Google Scholar
• Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. 90, 21–34 (2001).
   PubMed Web of Science ®Google Scholar
• Schachter SC. Current evidence indicates that antiepileptic drugs are anti-ictal, not antiepileptic. Epilepsy Res. 50, 67–70 (2002).
   PubMedGoogle Scholar
• Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42, 515–524 (2001).
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861–9866 (2004).
   PubMed Web of Science ®Google Scholar
• Tian G-F, Azmi H, Takano T et al. Astrocytic basis of epilepsy. Nature Med. 11, 973–981 (2005).
   PubMed Web of Science ®Google Scholar
• Semah F, Picot MC, Adam C et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51, 1256–1262 (1998).
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 42, 357–362 (2001).
   PubMedGoogle Scholar
• Wiebe S, Blume WT, Girvin JP et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 345, 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Martin RC, Kretzmer T, Palmer C et al. Risk to verbal memory following anterior temporal lobectomy in patients with severe left-sided hippocampal sclerosis. Arch. Neurol. 59, 1895–1901 (2002).
   PubMedGoogle Scholar
• Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 59(Suppl. 4), S15–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 59(Suppl. 4), S3–S14 (2002).
   PubMed Web of Science ®Google Scholar
• Kossoff EH. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 3, 415–420 (2004).
   PubMed Web of Science ®Google Scholar
• Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46, 272–279 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46, 858–877 (2005).
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. (In Press) (2006).
   Google Scholar
• Berg AT, Langfitt J, Shinnar S et al. How long does it take for partial epilepsy to become intractable? Neurology 60, 186–190 (2003).
   PubMed Web of Science ®Google Scholar
• Remy S, Gabriel S, Urban BW et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol. 53, 469–479 (2003).
   PubMed Web of Science ®Google Scholar
• Loup F, Wieser HG, Yonekawa Y, Aguzzi A, Fritschy JM. Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. J. Neurosci. 20, 5401–5419 (2000).
   PubMedGoogle Scholar
• Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301, 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol. 16, 197–201 (2003).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46, 225–235 (2005).
   Google Scholar
• Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Sem. Cancer Biol. 8, 161–170 (1997).
   PubMed Web of Science ®Google Scholar
• Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36, 1–6 (1995).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Lin WR, Harding BN, Squier MC, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125, 22–31 (2002).
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442–1448 (2003).
   PubMed Web of Science ®Google Scholar
• Zimprich F, Sunder-Plassmann R, Stogmann E et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63, 1087–1089 (2004).
   PubMed Web of Science ®Google Scholar
• Tan NC, Heron SE, Scheffer IE et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Sills GJ, Mohanraj R, Butler E et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46, 643–647 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41, 81–92 (2002).
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129–134 (1995).
   PubMed Web of Science ®Google Scholar
• Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 282, 73–76 (2000).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 23, 393–398 (2000).
   PubMed Web of Science ®Google Scholar
• Biervert C, Schroeder BC, Kubisch C et al. A potassium channel mutation in neonatal human epilepsy. Science 279, 403–406 (1998).
   PubMed Web of Science ®Google Scholar
• Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nature Genet. 18, 25–29 (1998).
   PubMed Web of Science ®Google Scholar
• Charlier C, Singh NA, Ryan SG et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nature Genet. 18, 53–55 (1998).
   PubMed Web of Science ®Google Scholar
• Sólyom S, Tarnawa I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. 8, 913–939 (2002).
   PubMed Web of Science ®Google Scholar
• Vilagi I, Takacs J, Gulyas-Kovacs A, Banczerowski-Pelyhe I, Tarnawa I. Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. 59, 35–40 (2002).
   PubMed Web of Science ®Google Scholar
• Erdo F, Berzsenyi P, Andrasi F. The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia. Brain Res. Bull. 66, 43–49 (2005).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1–48 (2004).
   PubMed Web of Science ®Google Scholar
• Matagne A, Michel P, Kenda B, Klitgaard H. Seletracetam (ucb 44212), a new pyrrolidone derivative, suppresses seizures in animal models of chronic epilepsy. Epilepsia 46(Suppl. 6), 121 (2005).
   Google Scholar
• Avendaño C, Menéndez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Medic. Chem. 9, 159–193 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10, 159–165 (2003).
   PubMedGoogle Scholar
• Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128, 403–411 (1999).
   PubMed Web of Science ®Google Scholar
• Brandt C, Bethmann K, Gastens A, Löscher W. Resistance to antiepileptic drug treatment can be counteracted by inhibition of P-glycoprotein in a rat model of temporal lobe epilepsy. Epilepsia 46(Suppl. 6), 60 (2005).
   Google Scholar
• Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 16, 579–593 (2002).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31–71 (2002).
   PubMed Web of Science ®Google Scholar
• Barton ME, White HS. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res. 59, 1–12 (2004).
   PubMedGoogle Scholar
• Lu XC, Williams AJ, Wagstaff JD, Tortella FC, Hartings JA. Effects of delayed intrathecal infusion of an NMDA receptor antagonist on ischemic injury and peri-infarct depolarizations. Brain Res. 1056, 200–208 (2005).
   PubMedGoogle Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug Dis. 4, 145–160 (2005).
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2, 99–107 (2005).
   PubMedGoogle Scholar
• Mori N, Kurokouchi A, Osonoe K et al. Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res. 703, 184–190 (1995).
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg. 41, 44–48 (1997).
   PubMed Web of Science ®Google Scholar
• Boison D, Scheurer L, Tseng JL, Aebischer P, Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol. 160, 164–174 (1999).
   PubMed Web of Science ®Google Scholar
• Kokaia M, Aebischer P, Elmer E et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp. Brain Res. 100, 385–394 (1994).
   PubMed Web of Science ®Google Scholar
• Tamargo RJ, Rossell LA, Kossoff EH et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res. 48, 145–155 (2002).
   PubMed Web of Science ®Google Scholar
• Hamani C, Hodaie M, Lozano AM. Present and future of deep brain stimulation for refractory epilepsy. Acta Neurochir. 147, 227–229 (2005).
   PubMedGoogle Scholar
• Velasco F, Velasco M, Velasco AL, Jimenez F, Marquez I, Rise M. Electrical stimulation of the centromedian thalamic nucleus in control of seizures: long-term studies. Epilepsia 36, 63–71 (1995).
   PubMed Web of Science ®Google Scholar
• Kerrigan JF, Litt B, Fisher RS et al. Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy. Epilepsia 45, 346–354 (2004).
   PubMed Web of Science ®Google Scholar
• Benabid AL, Minotti L, Koudsie A, de Saint Martin A, Hirsch E. Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luysi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. Neurosurgery 50, 1385–1391 (2002).
   PubMed Web of Science ®Google Scholar
• Velasco F, Carrillo-Ruiz JD, Brito F et al. Double-blind, randomized controlled pilot study of bilateral cerebellar stimulation for treatment of intractable motor seizures. Epilepsia 46, 1071–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Yonch K, Boon P, Achten E et al. Long term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. Ann. Neurol. 52, 556–565 (2002).
   PubMedGoogle Scholar
• Theodore WH, Fisher RS. Brain stimulation for epilepsy. Lancet Neurol. 3, 111–118 (2004).
   PubMed Web of Science ®Google Scholar
• Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy Res. 39, 103–114 (2000).
   PubMedGoogle Scholar
• Fountas KV, Smith JR, Murro AM, Politsky J, Park JD, Jenkins PD. Implantation of a closed-loop stimulation in the management of medically refractory focal epilepsy. Stereotact. Funct. Neurosurg. 83, 153–158 (2005).
   PubMed Web of Science ®Google Scholar
• Litt B, Echauz J. Prediction of epileptic seizures. Lancet Neurol. 1, 22–30 (2002).
   PubMed Web of Science ®Google Scholar
• Shetty AK, Turner DA. Fetal hippocampal grafts containing CA3 cells restore host hippocampal glutamate decarboxylase-positive interneuron numbers in a rat model of temporal lobe epilepsy. J. Neurosci. 20, 8788–8801 (2000).
   PubMed Web of Science ®Google Scholar
• Löscher W, Ebert U, Lehmann H et al. Seizure suppression in kindling epilepsy by grats of fetal GABAergic neurons in rat substantia nigra. J. Neurosci. Res. 51, 196–209 (1998).
   PubMed Web of Science ®Google Scholar
• Huber A, Padrun V, Déglon N et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl Acad. Sci. USA 98, 7611–7616 (2001).
   PubMed Web of Science ®Google Scholar
• Güttinger M, Fedele D, Koch P et al. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia 46, 1162–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Chu K, Kim M, Jung KH et al. Human neural stem cell transplantation reduces spontaneous recurrent seizures following pilocarpine-induced status epilepticus in adult rats. Brain Res. 1023, 213–221 (2004).
   PubMed Web of Science ®Google Scholar
• Haberman RP, Samulski RJ, McCown TJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nature Med. 9, 1076–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Richichi C, Lin E-J D, Stefanin D et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24, 3051–3059 (2004).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 60(Suppl. 4), S2–S12 (2003).
   PubMedGoogle Scholar
• Luszczki JJ, Czuczwar SJ. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 45, 895–907 (2004).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Yuen AWC and the 105 Study Group. Lamotrigine substitution study: synergism with sodium valproate? Epilepsy Res. 26, 423–432 (1997).
   PubMed Web of Science ®Google Scholar
• Pisani F, Otero G, Russo MF. Di Perri R, Perucca E, Richens A. The efficacy of valproate–lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40, 1141–1146 (1999).
   PubMed Web of Science ®Google Scholar